

Emily E Van Seventer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556320/publications.pdf>

Version: 2024-02-01

41
papers

2,545
citations

567281

15
h-index

414414

32
g-index

44
all docs

44
docs citations

44
times ranked

5224
citing authors

#	ARTICLE	IF	CITATIONS
1	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686
2	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	9.4	384
3	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
4	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	9.4	256
5	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with <i>FGFR2</i> Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	9.4	254
6	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	13.2	112
7	Response to Anti-EGFR Therapy in Patients with <i>BRAF</i> non-V600-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7089-7097.	7.0	79
8	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67
9	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	7.0	64
10	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> V600E Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	9.4	61
11	Computed Tomography-based Body Composition Analysis and Its Role in Lung Cancer Care. <i>Journal of Thoracic Imaging</i> , 2020, 35, 91-100.	1.5	39
12	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	3.0	30
13	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	9.4	30
14	A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3514-3514.	1.6	28
15	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	17
16	A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3602-3602.	1.6	12
17	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. <i>Oncologist</i> , 2021, 26, e963-e970.	3.7	9
18	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	2.9	9

#	ARTICLE	IF	CITATIONS
19	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	7.0	8
20	A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 391-391.	1.6	8
21	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	4.1	7
22	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	1.6	7
23	Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 515-515.	1.6	3
24	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562.	1.6	2
25	Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 659-659.	1.6	2
26	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3563-3563.	1.6	2
27	Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 149-149.	1.6	2
28	Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3565-3565.	1.6	1
29	Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 753-753.	1.6	1
30	Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 393-393.	1.6	1
31	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 84-84.	1.6	1
32	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6560-6560.	1.6	0
33	Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 180-180.	1.6	0
34	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154.	1.6	0
35	Increased T-cell receptor repertoire diversity to predict better overall survival in gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 474-474.	1.6	0
36	Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3590-3590.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer.. Journal of Clinical Oncology, 2019, 37, 3057-3057.	1.6	0
38	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2020, 38, 833-833.	1.6	0
39	Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 7006-7006.	1.6	0
40	Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.. Journal of Clinical Oncology, 2020, 38, 2013-2013.	1.6	0
41	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	0